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Abbreviation lists 
BioES: Biolimus eluting stent  
BMS: bare metal stents  
CABG coronary artery bypass graft  
DES drug-eluting stents 
EES: Everolimus eluting stent  
MI myocardial infarction 
PCI percutaneous coronary intervention  
PES: paclitaxel-eluting stents (PES)  
RCT randomized controlled trials  
SES: sirolimus-eluting stents 
LMD left main disease  
ZES: zotarolimus-eluting stents   
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Central message: The introduction of new generation drug eluting stents for 
unprotected left main disease did not translated into better clinical outcomes compared 
to coronary artery bypass surgery.    
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Prospective statement: Whether the evolution of stents technology has translated 
into better results after percutaneous coronary intervention for unprotected left main 
disease remains unclear. The present network meta-analysis suggests that new 
generation stents are not associated with better outcomes when compared to coronary 
artery bypass surgery.    
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Abstract 
Background: With the advent of bare metal stents (BMSs) and drug-eluting stents 
(DESs), percutaneous coronary intervention (PCI) has emerged as an alternative to 
coronary artery bypass graft (CABG) surgery for unprotected left main disease (LMD).  
However, whether the evolution of stents technology has translated into better results 
after PCI remains unclear. We aimed to compare CABG with stents of different 
generations for LMD by performing a Bayesian network meta-analysis (NMA) of 
available randomized controlled trials (RCT).  
Methods: All RCTs with at least 1 arm randomized to PCI and/or CABG for LMD were 
included. Poisson methods and Bayesian framework was used to compute head-to-
head incidence rate ratio (IRR) and 95% credible intervals (CrIs). Primary endpoint 
were the composite of death/myocardial infarction (MI)/stroke and repeat 
revascularization.  
Results: Nine were included in the final analysis. Overall, 6 studies compared PCI and 
CABG (n=4,654) and other three compared different type of stents (n=1,360). Follow-
up ranged from 6 moths to 5 years. BMS (IRR 0.63; 95%CrI 0.27-1.4) and 1st 
generation DES (IRR 0.85;9%%CrI 0.65-1.1) did not significantly differ from CABG for 
the composite of death/MI/stroke. Surprisingly, 2nd generation DES were associated 
with a significantly increase the risk of death/MI/stroke when compared to CABG (IRR 
1.3; 95%CrI 1.1-1.6). Moreover, while 1st generation DES (IRR 1.8; 95%CI 1.4-2.4) 
narrowed the gap between CABG and PCI in terms of repeat revascularization when 
compared to BMS (HR 5.1; 95%CI 2.1-14), the risk of a further reintervention did not 
further improve with 2nd generation DES (IRR 1.8; 95%CI 1.4-2.4).  
Conclusions: The introduction of new generation DES did not translate into better 
outcome from PCI when compared to CABG.  
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Introduction 
Coronary artery bypass grafting (CABG) has long been considered superior to 
percutaneous coronary intervention (PCI) in the treatment of choice for unprotected 
left main disease (LMD)1.  However, with the advent of bare metal stents (BMS) and 
first-generation drug eluting stents (DES) including paclitaxel-eluting stents (PES) and 
sirolimus-eluting stents (SES), PCI has emerged as an attractive alternative 1,2. The 
recent introduction of second generation DES including everolimus-eluting stents 
(EES), and zotarolimus-eluting stents (ZES) and biodegradable polymer biolimus 
eluting stent (Bio-ES) has further promoted PCI in this setting3.  
However, whether the evolution of stents technology has translated into better results 
after PCI remains unclear. Despite the lack of definitive evidence on the equipoise 
between PCI with 2nd generation DES and CABG in terms of hard clinical endpoints, 
the current trend is preferring PCI to CABG when technically feasible.   
We aimed to compare CABG with stents of different generations for LMD by 
performing a Bayesian network meta-analysis (NMA) of available randomized 
controlled trials (RCT).  
Material and methods 
This work was designed as a systematic review and network meta-analysis, with 
reporting following the Preferred Reporting Items for Systematic Reviews and Meta-
Analysis statement4-6.  
Data sources and searches 
We searched PubMed, the Cochrane Central Register of Controlled Trials, and 
EMBASE from their inception to November 2016, without language restrictions. 
Search algorithm used was "Left main" AND ("percutaneous coronary intervention" 
OR PCI OR stent*) AND ("coronary artery bypass" OR CABG OR "bypass surgery" 
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OR "coronary bypass"). Reference lists of the identified reports and relevant reviews 
were manually screened by 3 reviewers (UB, ADF, LBO) to identify further relevant 
studies. In addition, when other meta-analyses, systematic reviews, or RCTs were 
found, we used backward snowballing (ie, scanning of references of retrieved articles 
and pertinent reviews) to obtain further studies. 
Study selection 
Investigators first examined references at the title/abstract level, with divergences 
resolved by consensus, and then, if potentially pertinent, retrieved the complete 
articles. Articles were included in the present analysis if they fulfilled the following 
inclusion criteria: random allocation to treatment, at least 1 group randomized to CABG 
and/or PCI for LMD. 
Data extraction and quality assessment 
Baseline including SYNTAX score7, procedural, outcome, and follow-up data were 
independently abstracted by 2 investigators. In the present analysis outcomes were 
adjudicated according to the original authors’ definitions. Outcomes were analysed 
according to the intention-to-treat principle whenever possible. The internal validity 
and risk of bias of included trials were appraised by 2 independent investigators (U.B, 
M.K) according to the “risk of bias assessment tool” developed by the Cochrane 
collaboration8. Briefly, for each trial, 7 domains were assessed: random sequence 
generation, allocation concealment, blinding of participants and personnel, blinding of 
outcome assessors, incomplete outcome data reporting, selective reporting, and 
presence of other bias. Presence of possible source of bias in each domain was 
assessed, and a final judgment of low, moderate, or high risk of bias was assigned. 
Endpoints 
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Primary endpoint was the commonly adopted composite of death, myocardial 
infarction (MI) or stroke (death/MI/stroke) at longest follow-up available. As 2nd 
generation stents are anticipated to reduce the risk of restenosis, repeat 
revascularization was also considered a primary endpoint. Secondary endpoints were: 
mortality and MI.  
Data synthesis and analysis 
The network meta-analysis was conducted using R (version 3.2.0, R Project for 
Statistical Computing) with the gemtc and rjags packages, which interface with 
Just Another Gibbs Sampler (JAGS) software (version 3.4.0). Two separate 
analyses were conducted. The first analysis compared different stents 
generations against CABG and stents were categorized in three groups: BMS, 
1st generation stents which included PES and SES and finally 2nd generation 
stents which included BioES, EES and ZES.  The second analysis compared 
individual stents against CABG.  
When modelling the clinical outcomes of interest, it is important to consider the 
different follow up times of the various trials, as longer follow up is likely to result in 
more reported events. To account for this, an underlying Poisson process with a 
constant event rate was assumed with total number of events observed within a 
treatment group out of the total person-time of follow-up for that treatment group 
calculated from study follow up. A log link function was used to model the incidence 
rate.  
Relative effect estimates from the NMA were calculated as log incidence rate ratios 
(IRR) with 95% credible intervals (CrIs). For all practical purposes, incidence rates can 
be thought of as hazards and thus the IRR can be roughly interpreted as hazard ratio. 
Incidence of primary endpoints observed in each treatment arm for each included trial 
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was extracted and pooled using the Bayesian fixed effects model9. A fixed effects 
model was chosen because it had a lower deviance information criterion (DIC) 
compared to the random effects model, suggesting a better model fit. Non-informative 
prior distributions were chosen for model parameters so that results were driven 
entirely by the reported data. Analyses were performed using Markov-Chain Monte-
Carlo methods, a method that estimates the effect of each treatment comparison by 
simulation, using four chains with 100,000 iterations and thinning interval of ten, after 
a burn-in of 50,0009. Convergence of the chains was assessed using the Gelman plot 
and diagnostic test10. Statistical significance was considered when the CrIs did not 
cross the line of no effect.  The effect of SYNTAX score on treatment effect was 
investigated using meta-regression analysis as proposed by Gelman et al. 11  
Consistency  
An assumption of NMA models is that direct and indirect sources of evidence estimate 
the same true treatment effect. This was evaluated by conducting conventional 
pairwise meta-analyses and testing consistency by comparing the direct and indirect 
evidence results to see if a statistically significant difference existed. We applied the 
back-calculation method to check for consistency within the evidence networks12. 
Based on the back-calculation method, the difference between direct and indirect 
estimate was considered as an estimate of inconsistency. Our null hypothesis was 
that there was consistency between the direct and indirect evidence and we would 
reject the null hypothesis if there was a statistically significant difference between the 
direct and indirect evidence comparison (p<0.05). 
As secondary analysis, a pairwise meta-analysis was conducted to pool data from 
RCT comparing PCI versus CABG for primary endpoints with subgroup analysis 
according to type of stents used. We derived the log IRR and corresponding standard 
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error from numbers of reported events and accumulated person-years of follow-up. 
Finally log IRR were pooled using the generic inverse variance method with random 
and fixed model. Hypothesis of statistical heterogeneity was tested by means of 
Cochran Q test, with statistical significance set at the two-tailed 0.10 level, while extent 
of statistical consistency was measured with I2, defined as 100% X (Q-df)/Q, where Q 
is Cochran’s heterogeneity statistic and the degrees of freedom.  
Results 
Of 2597 potentially relevant articles initially screened, nine met the inclusion criteria 
and were included in the final analysis 1-3, 13-18 (Figure 1). Flow diagram of study 
selection is reported in Supplementary Figure 1. Overview of study characteristics in 
individual RCT is reported in Table 1 and Supplementary Table 1 and Supplementary 
Table 2. Internal validity assessment for each trial are reported in Supplementary 
Table 3. Overall, 6 studies1-3,13-15 compared PCI and CABG (n=4,654) and other 
three16-18 compared different type of stents (n=1,360). Follow-up ranged from 6 moths 
to 5 years.  
Network meta-analysis 
NMA estimates for primary and secondary endpoints are reported in Figure 2 and 
Figure 3 and Supplementary Table 4.  BMS (IRR 0.63; 95%CrI 0.27-1.4) and 1st 
generation DES (IRR 0.85;9%%CrI 0.65-1.1) did not significantly differ from CABG for 
the composite of death/MI/stroke. Surprisingly, 2nd generation DES were associated 
with a significantly increase the risk of death/MI/stroke when compared to CABG (IRR 
1.3; 95%CrI 1.1-1.6). This result was driven by a significantly increased risk of MI with 
BioES (IRR 3.0; 95%CrI 1.5-6.4), a non-significant excess of death and MI with ZES 
and a marginally non-significant increased risk of death with EES (IRR 1.4; 95%CrI 
0.97-1.9).    
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We also found that while the introduction of 1st generation DES (IRR 1.8; 95%CI 1.4-
2.4) narrowed the gap between CABG and PCI in terms of repeat revascularization 
when compared to BMS (HR 5.1; 95%CI 2.1-14), the risk of a further reintervention 
did not further improve with 2nd generation DES (IRR 1.8; 95%CI 1.4-2.4).  
The comparison between CABG and different type of stents was constant across 
SYNTAX score values for both the composite of death/MI/stroke and repeat 
revascularization (Supplementary Figure 2 and 3). No inconsistency was found 
between direct and indirect comparison expect for a marginally significant difference 
for the composite of death/MI/stroke between BMS vs CABG and BMS vs PES 
(Supplementary Figure 4) 
Pairwise meta-analysis PCI vs CABG 
Pairwise comparison between PCI and CABG was based on 6 RCTs. Overall, PCI 
and CABG were comparable for death/MI/stroke (IRR 0.99; 95%CI 0.70-1.4). 
However, while 1st generation DES were associated with a non-significant 11% relative 
risk reduction of death/MI/stroke when compared to CABG, 2nd generation DES were 
associated with a 33% relative risk increase. Pairwise comparison confirmed that 1st 
generation DES (IRR 1.82; 95%CI 1.39-2.4) and 2nd generation DES (HR 1.79; 95%CI 
1.42-2.2) presented comparable incidence rate ratio for repeat revascularization when 
compared to CABG.  
Discussion 
The main finding of the present NMA was that the introduction of 2nd generation DESs 
did not improve PCI outcomes when compared to CABG for unprotected LMD. 
Surprisingly 2nd generation DESs were associated with a significant trend towards an 
increased risk of death/MI/stroke when compared to CABG while this was not 
observed with BMS or 1st generation stents (SES and PES). When outcomes from 
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individual stents were analysed separately, we found that BioES was associated with 
a significant 3-fold increased risk of MI, ZES showed a non-significant trend towards 
increased risk of mortality and MI and EES showed a marginally non-significant 
increased risk of mortality.  
Finally, we found that while the introduction of 1st generation DESs narrowed the gap 
between CABG and PCI in terms of repeat revascularization when compared to BMS, 
the risk of a further reintervention did not further improve with 2nd generation DESs. 
Concern about the long-term safety of DESs for unprotected LMD disease has been 
raised in the past due to the observed risk of stent thrombosis which may outweigh 
the benefits of DESs 19-21. Despite the SYNTAX trial3 and the PRECOMBACT trail9 
has shown comparable results between first generation DESs and CABG for 
unprotected LMD, these studies were largely underpowered to detect difference in 
hard clinical endpoints such as death and MI. New generation DES including polymer 
BioES and EES and have been introduced to replace first generation DES with more 
biocompatible and thinner polymers to reduce of stent thrombosis rates21. However, 
two recent large RCTs, NOBLE1 and EXCEL2, compared BioES and EES respectively 
versus CABG reaching conflicting conclusions about the non-inferiority of PCI over 
CABG. Such a discrepancy can be partially related to different definitions adopted for 
MI. In fact, for the primary endpoint definition, the NOBLE trail included non-procedural 
MI only while EXCEL, SYNTAX and PRECOMBAT included both procedural and 
subsequent spontaneous MI. However, PCI-related MI has a greater impact on long 
term prognosis than CABG-related MI and there is still controversy on which unifying 
common definition for PCI-related and CABG-related MI should be adopted22.  This 
aspect calls into question the validity of endpoints definitions which include peri-
procedural MI in the comparison between PCI and CABG. Of notice, in EXCEL, while 
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the two strategies did not differ for the composite of procedural and spontaneous MI, 
PCI was associated with an increased risk of subsequent spontaneous MI when 
compared to CABG.   
Second generation DESs including EES and BioES have been developed to improve 
PCI outcomes achieved with 1st generation DESs by reducing the risk of stent 
thrombosis and restenosis and several investigations have confirmed their efficacy23.  
However, it must be noticed that in the vast majority of these studies, 2nd generation 
DESs have been used to treat distal targets. We can speculate that the superiority of 
2nd generation over 1st generations DESs might not be reproducible in LMD. It has 
been shown that the risk of restenosis might be less relevant in case of coronary 
arteries with larger diameter (≥ 3.5 mm)24 and this aspect can partially explain the lack 
of benefit in terms of repeat revascularization with 2nd generation DES observed in the 
present NMA.  
On the other hand, BioESs have been perceived as safer than 1st generation DESs, 
mainly on the basis of results from individual trials powered only for composite 
endpoints of safety and efficacy25. However, a recent landmark NMA26 concluded that 
BioES is associated with an excess of death and MI when compared to other durable 
polymer DESs. Biodegradable polymer DESs such as BioES employs polymers that 
dissolve after time in which antiproliferative drug elution is needed. Once the 
degradation process of the polymer is completed in these devices, what remains is a 
bare-metal scaffold with thick-struts design. This platform may provide lower elasticity 
than durable polymers, with an increased risk of fragility and micro-damage to the 
coating, and potential “jailing” of side branches. these factors explain the lower safety 
profile with biolimus biodegradable polymer stents26.  
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As with any meta-analysis, our report shares the limitations of the original studies. By 
exploiting potentially complex evidence networks along with indirect and direct 
comparisons, network meta-analysis assumes that patients enrolled in the component 
studies were sampled from the same theoretical population and that similar 
comparators between different trials have a consistent risk-benefit ratio.  
In the present analysis, some studies have a limited sample size and there was a 
relatively small number of trials for the comparison of individual stents against CABG. 
As a consequence, few comparisons present relatively wide confidence interval 
(unaddressed uncertainty). However, no inconsistencies were apparent between the 
direct and indirect estimates for the endpoints considered across all comparisons, 
which provides strong scientific support for the reliability of the network. Results were 
analysed on aggregate data, and therefore, we could not assess whether all baseline 
characteristics were balanced between the groups. Finally, several comparisons were 
of borderline statistical significance, and even greater numbers of patients with longer-
term follow-up would add greater precision to the present results. 
In conclusion, a word of caution should be exercised on the current trend of preferring 
PCI with new generation DESs over CABG for LMD in view of the present findings. 
We did not demonstrate the anticipated benefit from 2nd generation DESs in this 
population in terms of mortality, MI and repeat revascularization. The routine use of 
new generation DESs in the treatment of LMD still deserves further investigations. 
Current trials are largely underpowered to clarify whether DESs are as safe as CABG 
in terms of mortality and the use of endpoints including procedural MI might have 
masked potential risks with DESs. Adequately powered and well-designed studies are 
needed to guide clinician in decision making. Finally concerns remain as most of 
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clinical research studies are funded by manufacturers with the relative risk of bias in 
favour of a new devices.  
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Table 1. Characteristics of randomized controlled trials included in the network meta-analysis  1 
Trial Year 
Treatment 
received 
EuroSCORE 
(PCI) 
EuroSCORE 
(CABG) 
SYNTAX 
(PCI) 
SYNTAX 
(CABG) 
Not isolated 
LMD, % 
Distal 
LMD, % 
Follow-up 
(years) 
NOBLE 2016 CABG vs Bio-ES 2 (2, 4) 2 (2, 4) 22.5±7.5 22.4±8.0 NA 81 3.1 
EXCEL 2016 CABG vs EES NA NA 26.9±8.8 26.0±9.8 82.2 79.2 3 
LE MANS 2016 CABG vs BMS 3.3±2.3 3.5±2.3 25.2±8.7 24.7±6.8 94 60 1 
PRECOMBAT 2015 CABG vs SES 2.6±1.8 2.8±1.9 24.4±9.4 25.8±10.5 NA 67 5 
SYNTAX 2014 CABG vs PES 3.9±2.8 3.9±2.9 29.6±13.5 30.2±12.7 85.9 58.3 5 
Boudriot, et al 2011 CABG vs SES 2.4 (1.5, 3.7) 2.6 (1.7, 4.9) 24.0 (19.0, 29.0) 23.0 (14.8, 28.0) 71 69 1 
Erglis et al. 2007 BMS vs PES NA - 32.6±11.7 - 49 75% 0.5 
ISAR-LEFT-MAIN 2009 PES vs SES 4.7±3.4 - NA - NA 64% 1 
ISAR-LEFT-MAIN 2 2013 ZES vs EES 5.1 ± 3.7  NA - NA 79% 1 
Values are mean, median (interquartile range), or %. PCI: percutaneous coronary intervention; CABG = coronary artery bypass graft surgery; FU = follow-up; LMD = left main 2 
disease;; NA = not available;BioES: Biolimus eluting stent; BMS: bare metal stents; EES: Everolimus eluting stent; PES: paclitaxel-eluting stents; SES: sirolimus-eluting stents; 3 
ZES: zotarolimus-eluting stent 4 
Expanded study abbreviations are as follows: EXCEL = the Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization 5 
trial; LE MANS = Study of UnprotectedLeft Main Stenting Versus Bypass Surgery; NOBLE = The Nordic-Baltic-British left main revascularisation study; PRECOMBAT = the 6 
Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease trial; SYNTAX = 7 
the other Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery trial. ISAR-LEFT-MAIN (Intracoronary Stenting and Angiographic Results: 8 
Drug-Eluting Stents for Unprotected Coronary Left Main Lesions 9 
  10 
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Supplementary Table 1. Main inclusion and exclusion criteria, primary and secondary endpoints of randomized controlled trials. 11 
Trial Main inclusion criteria Main exclusion criteria Primary endpoint Secondary endpoint 
NOBLE  stable angina pectoris, unstable angina 
pectoris, or acute coronary syndrome, 
together with a lesion with visually 
assessed stenosis diameter ≥50% or 
fractional flow reserve ≤0·80 in the left 
main coronary artery ostium, mid-shaft, or 
bifurcation, with no more than three 
additional noncomplex lesions. 
ST-elevation infarction within 24 h, being 
considered too high risk for CABG or PCI, or 
expected survival of less than 1 year. 
Composite of major 
adverse cardiac and 
cerebrovascular events 
(MACCE; death from any 
cause, non-procedural 
myocardial infarction, 
repeat revascularisation, or 
stroke). 
The individual component of 
the primary MACCE endpoint, 
definite stent thrombosis, and 
symptomatic graft occlusion. 
Procedural myocardial 
infarctions were documented 
(post hoc). Repeat 
revascularisations. 
EXCEL Stenosis of the left main coronary artery of 
70% or more, as estimated visually, or 
stenosis of 50% to less than 70% if 
determined by means of noninvasive or 
invasive testing to be hemodynamically 
significant, and a consensus among the 
members of the heart team regarding 
eligibility for revascularization with either 
PCI or CABG. In addition, participants 
were required to have low-to-intermediate 
anatomical complexity of coronary artery 
disease, as defined by a site-determined 
SYNTAX score of 32 or lower (the 
SYNTAX score reflects a comprehensive 
angiographic assessment of the coronary 
vasculature, with 0 as the lowest score and 
higher scores [no upper limit] indicating 
more complex coronary anatomy). 
Prior PCI of the left main trunk at any time prior to 
randomization, PCI of any other (non-left main) 
coronary artery lesions within one year prior to 
randomization, CABG at any time prior to 
randomization. Need for any concomitant cardiac 
surgery other than CABG. 
Angiographic exclusion criteria: a. Left main 
diameter stenosis <50%, unless left main 
equivalent disease is present; b. SYNTAX score 
≥33, as determined by the local Heart Team; c. 
Visually estimated left main reference vessel 
diameter <2.25 mm or >4.25 mm  
d. The presence of specific coronary lesion 
characteristics or other cardiac condition(s) which 
leads the participating interventional cardiologist or 
cardiac surgeon to believe that clinical equipoise is 
not present 
the primary composite end 
point of death from any 
cause, stroke, or 
myocardial infarction 
a composite of death from any 
cause, stroke, or myocardial 
infarction at 30 days and the 
rate of a composite of death, 
stroke, myocardial infarction, or 
ischemia-driven 
revascularization at 3 years. 
Additional secondary end 
points included the 
components of the primary end 
point, as well as 
revascularization, stent 
thrombosis, symptomatic graft 
stenosis or occlusion, bleeding 
complications, and a 
prespecified composite of 
periprocedural major adverse 
events. 
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LE MANS Patients with >50% narrowing of ULMCA, 
with or without multivessel coronary artery 
disease suitable for equal 
revascularization both with PCI and CABG. 
All patients had to be symptomatic with 
documented myocardial ischemia. 
Acute myocardial infarction, total occlusion of left 
main, comorbid conditions, or coronary anatomic 
considerationsthat increased the surgical risk to a 
Euroscore of 8 or more, stroke or transient ischemic 
attack within 3 months, renal dysfunction, or 
contraindication to antiplatelet therapy. 
The change in LVEF 
assessed by 2-dimensional 
echocardiography 12 
months 
MACCE (Major adverse 
cardiac and cerebrovascular 
events), MAE (other major 
adverse events) length of 
hospitalization, exercise 
tolerance measured with an 
electrocardio graphic treadmill 
stress test along with angina 
severity according to the 
Canadian Cardiovascular 
Society classification after 1 
year, total survival, target 
vessel failure (TVF) and 
revascularization (TVR). 
PRECOMBAT  Older than 18 years of age and had 
received a diagnosis of stable angina, 
unstable angina, silent ischemia, or non–
ST-segment elevation MI. All patients had 
newly diagnosed ULMCA stenosis (more 
than 50% diameter stenosis by visual 
angiographic estimation) and had been 
judged to be suitable candidates for either 
PCI or CABG. 
Systemic (intravenous) sirolimus use within 12 
months. Any previous percutaneous coronary 
intervention (PCI) within 1 year. Previous bypass 
surgery. Any previous PCI of a ULMCA or ostial left 
circumflex artery or ostial left anterior descending 
artery lesion within 1 year. Acute MI within 1 week. 
Ejection fraction <30%. Cardiogenic shock. 
Composite of death from 
any cause, MI, stroke, or 
ischemia-driven target 
vessel revascularization 
[TVR]) 
The individual components of 
the primary endpoint; a 
composite of death, MI, or 
stroke; and clinically driven 
TVR. 
SYNTAX De novo lesions, ≥50% target vessel 
stenosis with stable/unstable angina or 
atypical chest pain. If asymptomatic, 
positive evidence of myocardial ischemia 
was required.  
Previous PCI or CABG, acute myocardial infarction 
(MI), or the need for concomitant cardiac surgery. 
Composite of major 
adverse cardiac and 
cerebrovascular events 
(i.e., death from any cause, 
stroke, myocardial 
infarction, or repeat 
revascularization) 
The individual component of 
the primary MACCE endpoint, 
Quality of life and 
costeffectiveness. 
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Boudriot, et al Patients age 18 to 80 years with stenosis 
(>50%) of the ULM with or without 
additional multivessel coronary artery 
disease were included in this multicenter 
study. Patients had to be symptomatic or 
have documented myocardial ischemia. 
Myocardial infarction48 h requiring immediate 
intervention, additional valvular heart disease 
requiring surgery, previous surgical treatment for 
coronary artery or valvular disease, severe 
peripheral arterial disease, significant carotid 
stenosis requiring treatment, renal dysfunction 
requiring dialysis, any disease with limited life 
expectancy, overt congestive heart failure, and 
contraindication to antiplatelet therapy. 
Angiographic exclusion criteria were total 
occlusions, extreme left-dominant coronary artery 
perfusion, and distal lesion length >30 mm in a 
single lesion 
Major adverse 
cardiovascular events, 
which included death from 
any cause, myocardial 
infarction, and the need for 
repeat revascularization 
Each individual component of 
the composite end point. 
     
Erglis et al. Eligible patients were those with clinically 
symptomatic LM disease with angiographic 
evidence of.>50% diameter stenosis of LM 
suitable for stent implantation. All patients 
were good candidates for CABG.  
CABG to left anterior descending (LAD) artery 
branches or left circumflex (LCX) branches 
neointimal growth (volume, 
square, luminal diameter, 
and late lumen loss) 
evaluated by IVUS at 6 
months, or earlier if 
clinically indicated.  
Major adverse cardiac events 
(MACE) were defined as death, 
myocardial infarction (MI), and 
target lesion revascularization 
(TLR) 
     
ISAR-LEFT-
MAIN 
patients older than age 18 years with 
ischemic symptoms or evidence of 
myocardial ischemia in the presence of 
>50% de novo stenosis located in the left 
main stem 
 
ST-segment elevation myocardial infarction (MI) 
within 48 h of symptom onset; prior bypass graft 
surgery; in-stent restenosis; cardiogenic shock; 
malignancies or other comorbid conditions with life 
expectancy <1 year or that might result in protocol 
noncompliance; left main size >4.5 mm; planned 
staged PCI procedure within 30 days from index 
PCI; planned elective surgical procedure 
necessitating interruption of clopidogrel during the 
first 6 months after enrollment; known allergy to the 
study medications: clopidogrel, rapamycin, 
paclitaxel, stainless steel, or cobalt alloy; 
pregnancy; or previous enrollment in this trial 
the combined incidence of 
death, myocardial 
infarction, and target lesion 
revascularization (TLR) at 
1 year 
angiographic restenosis on the 
basis of the LMCA area 
analysis at follow-up 
angiography 
 23 
 
     
ISAR-LEFT-
MAIN 2 
patients older than 18 years of age with 
ischemic symptoms or evidence of 
myocardial ischemia in the presence of 
>50% de novo stenosis located in the left 
main stem 
ST-segment elevation MI within <48 h of symptom 
onset; prior CABG surgery; in-stent restenosis; 
cardiogenic shock; malignancies or other comorbid 
conditions with a life 
expectancy <1 year; planned staged PCI procedure 
within 30 days of index PCI; planned elective 
surgical procedure necessitating interruption of 
P2Y12-receptor inhibitors 
during the first 6 months post-enrollment; known 
allergy to the study medications: everolimus, 
zotarolimus, or cobalt alloy; pregnancy; or previous 
enrollment in this trial 
combined incidence of 
death, myocardial 
infarction, and target lesion 
revascularization 
definite or probable stent 
thrombosis at 1 year and 
angiographic restenosis based 
on analysis of the left main 
coronary artery area at follow-
up angiography 
Expanded study abbreviations are as follows: : EXCEL = the Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization 12 
trial; LE MANS = Study of UnprotectedLeft Main Stenting Versus Bypass Surgery; NOBLE = The Nordic-Baltic-British left main revascularisation study; PRECOMBAT = the 13 
Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease trial; SYNTAX = 14 
the other Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery trial. ISAR-LEFT-MAIN (Intracoronary Stenting and Angiographic Results: 15 
Drug-Eluting Stents for Unprotected Coronary Left Main Lesions 16 
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Supplementary Table 2. Outcome definition in randomized controlled trials. 18 
NOBLE (The Nordic-Baltic-British left main revascularisation study) 
All–cause mortality: Death from any cause.  
Cardiac death: Cardiac death was defined as any death due to a suspected cardiac cause (myocardial infarction, low–output heart failure, fatal arrhythmia), unwitnessed death and 
death of unknown cause. All procedure–related deaths, including those related to concomitant treatment, were classified as cardiac death. The endpoint was included post hoc. 
(Modified from Cutlip et al. Circulation. 2007;115:2344–2351) The information on cause of death was obtained from hospital patient files, from general practitioners, or from families if 
no other source was available.  
Vascular death: Death caused by non–coronary vascular causes, including cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other 
vascular diseases. The endpoint was included post hoc. (Modified from Cutlip et al. Circulation. 2007;115:2344–2351) 
Non–procedure–related myocardial infarction: A rise in biochemical markers exceeding the decision limit for myocardial infarction (99th percentile including < 10% CV) with at least 
one of the following; (1) ischemic symptoms, (2) ECG changes indicative of ischemia (ST segment elevation or depression), and (3) development of a pathologic Q–wave with no 
relation to a PCI procedure.  
Repeat revascularization: Any new PCI or CABG operation performed during follow–up. If an index revascularisation was attempted or successful, any subsequent revascularisation 
was counted as repeat revascularisation. Attempted PCI was defined as an advancement of a wire in the coronary tree at least. Attempted CABG was defined as at least initiation of 
an index operation.  
Procedure–related biomarker release: The diagnosis of a procedure–related biomarker increase required a rise in total creatine kinase (CK) and/or Troponin–T/I. Due to the great 
heterogeneity of biomarkers and various assays used during the study in participating centres, this comparison was omitted from the final analysis. 
Procedural myocardial infarction: Diagnosis of procedural MI for both PCI and CABG patients was based on CK–MB elevations when available. Patients needed to have stable 
angina pectoris as the clinical indication OR a normal baseline CK–MB, TnI, TnT, or highly sensitive TnT, to be assessable for procedural MI. Diagnosis required a CK–MB value 
above 10 x URL or ULN to establish the diagnosis. The diagnosis could also be placed by the combination of a CK–MB value above 5 x URL or ULN, AND one or more of the 
following: (1) new pathological Q waves in at least 2 contiguous leads or new persistent non–rate–related left bundle branch block, or (2) angiographically documented graft or native 
coronary artery occlusion or new severe stenosis with thrombosis and/or diminished epicardial flow, or (3) imaging evidence of new loss of viable myocardium or new regional wall 
motion abnormality. The endpoint of procedural myocardial infarction was included post hoc and the definition was adapted to match the definition applied in the EXCEL trial on PCI 
vs. CABG for LMCA stenosis. Peri-procedural MI due to repeat revascularization during follow-up were assessed applying the 3rd Universal definition as CK-MB was not available in 
all event patients. A procedural MI according to this definition was counted as a non-index procedural myocardial infarction. 
Non-procedural myocardial infarction: Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Circulation 2012; 126: 2020–35. 
Target lesion revascularization: Repeat revascularisation by PCI of any target segment treated during the index procedure. A target lesion segment was defined as a stented or 
balloon treated segment and its 5 mm margins. 
LMCA revascularization: Any subsequent revascularisation by PCI of the segments within 5 mm of any treated segment related to the LMCA or the LMCA bifurcation. Any 
revascularisation by CABG of native LMCA including the LMCA bifurcation, or revascularisation of a graft supplying the left anterior descending artery or circumflex arteries. 
Definite stent thrombosis: Stent thromboses were categorized as acute, subacute, late and very late and as definite, probable and possible according to ARC criteria. (Cutlip et al. 
Circulation 2007;115:2344–51) 
Symptomatic graft occlusion: Diagnosis of symptomatic graft occlusion required it to be detected during a clinically indicated coronary angiography.  
Stroke: Ischemic or haemorrhagic cerebrovascular event verified by brain computed tomography (CT) or magnetic resonance imaging (MRI).  
Pulmonary embolus: The diagnosis of pulmonary embolus required verification by an appropriate computed tomography scan.  
EXCEL (the Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization 
trial) 
Death: The cause of death will be adjudicated as being due to cardiovascular causes, non-cardiovascular causes, or undetermined causes. 
Cardiovascular death includes sudden cardiac death, death due to acute MI, heart failure or cardiogenic shock, stroke, other cardiovascular causes, or bleeding 
Non-cardiovascular death is defined as any death with known cause not of cardiac or vascular causes 
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Undetermined cause of death refers to a death not attributable to one of the above categories of cardiovascular death or to a noncardiovascular cause. For this trial all deaths of 
undetermined cause will be included in the cardiovascular category 
Myocardial infarction (protocol definition): 
Post procedure MI: Defined as the occurrence within 72 hours after either PCI or CABG of either: 
CK-MB >10x upper reference limit (URL)*, OR 
CK-MB >5x URL*,  PLUS 
-new pathological Q waves in at least 2 contiguous leads or new persistent non-rate related LBBB, or 
-angiographically documented graft or native coronary artery occlusion or new severe stenosis with thrombosis and/or diminished epicardial flow, or 
-imaging evidence of new loss of viable myocardium or new regional wall motion abnormality 
Spontaneous MI: defined as the occurrence >72 hours after any PCI or CABG of: 
The rise and/or fall of cardiac biomarkers (CK-MB or troponin) >1x URL* PLUS: 
- ECG changes indicative of new ischemia [ST -segment elevation or depression, in the absence of other causes of ST -segment changes such as left ventricular hypertrophy (LVH) 
or bundle branch block (BBB)], or 
- Development of pathological Q waves (≥0.04 seconds in duration and ≥1 mm in depth) in ≥2 contiguous precordial leads or ≥2 adjacent limb leads) of the ECG, or 
- Angiographically documented graft or native coronary artery occlusion or new severe stenosis with thrombosis and/or diminished epicardial flow, or 
- Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality  
Each MI will also be adjudicated as:  
  ST-segment elevation MI (STEMI) 
  Non-ST-segment elevation MI (NSTEMI) 
  Each STEMI and NSTEMI will be subcategorized as 
-Q-wave 
-Non-Q-wave 
-Unknown (no ECG or ECG not interpretable) 
Stroke: The rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause 
(e.g., trauma, tumor, or infection). A vascular neurologist or stroke specialist will determine whether a stroke has occurred and determine the stroke severity using the NIHSS 
TIA/Stroke questionnaire. Available neuroimaging studies will be considered to support the clinical impression and to determine if there is a demonstrable lesion compatible with an 
acute stroke. Strokes will be classified as ischemic, hemorrhagic, or unknown. Four criteria must be fulfilled to diagnosis stroke: 
1. Rapid onset of a focal/global neurological deficit with at least one of the following: change in level of consciousness, hemiplegia, hemiparesis, numbness or sensory loss affecting 
one side of the body, dysphasia/aphasia, hemianopia, amaurosis fugax, other new neurological sign(s)/symptom(s) consistent with stroke; and 
  2. Duration of a focal/global neurological deficit ≥24 hours or <24 hours if any of the following conditions exist: 
i. At least one of the following therapeutic interventions: 
a. Pharmacologic (i.e., thrombolytic  drug administration) 
b. Non-pharmacologic (i.e., neurointerventional procedure such as intracranial angioplasty) 
ii. Available brain imaging clearly documents a new hemorrhage or infarct  
iii. The neurological deficit results in death 
  3. No other readily identifiable non-stroke cause for the clinical presentation (e.g., brain tumor, trauma, infection, hypoglycemia, other metabolic abnormality, peripheral lesion, or 
drug side effect). Patients with non-focal global encephalopathy will not be reported as a stroke without unequivocal evidence based upon neuroimaging studies. 
4. Confirmation of the diagnosis by a neurology  or neurosurgical specialist and at least one of the following: 
a. Brain imaging procedure  (at least one of the following): 
i. CT scan  
ii. M RI scan 
iii. Cerebral vessel angiography 
b. Lumbar puncture (i.e. spinal fluid analysis diagnostic of intracranial hemorrhage) 
 26 
 
All strokes with stroke disability of modified Rankin Scale (mRS) ≥1 (increase from baseline assessment) will be included in the primary endpoint. All diagnosed strokes (even with 
mRS 0) will also be tabulated. 
Ischemia-driven revascularization: 
A coronary revascularization procedure may be either a CABG or a PCI. The coronary segments revascularized will be sub-classified as: 
 Target Lesion: A lesion revascularized in the index procedure (or during a planned or provisional staged procedure). The LM target lesion extends from the left main stem ostium to 
the end of the 5 mm proximal segments of the left anterior descending and left circumflex arteries as well as the ramus intermedius if the latter vessel has a vessel diameter of ≥2 mm. 
 Target Vessel: The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion including upstream and downstream branches and the target 
lesion itself. The left main and any vessel originating from the left main coronary artery or its major branches is, by definition, considered a target vessel for the purposes of this trial 
(unless either the LAD or LCX are occluded at baseline and no attempt was made to revascularize these territories by either PCI or CABG). 
 Target Vessel Non-Target Lesion: The target vessel non-target lesion consists of a lesion in the epicardial vessel/branch/graft that contains the target lesion; however, this lesion is 
outside of the target lesion by at least 5 mm distal or proximal to the target lesion determined by quantitative coronary angiography (QCA). 
 Non-Target Vessel: For the purposes of this trial, the only possible non-target vessel would be the right coronary artery and its major branches that were not treated by either PCI or 
CABG at the index procedure (unless either the LAD or LCX are occluded at baseline and no attempt was made to revascularize these territories by either PCI or CABG). 
All revascularization events will be adjudicated as either ischemia -driven or non-ischemia -driven. Revascularization will be considered ischemia driven if the diameter stenosis of the 
revascularized coronary segment is ≥50% by QCA and any of the following criteria for ischemia are met: 
•A positive functional study corresponding to the area served by the target lesion; or 
•Ischemic ECG changes at rest in a distribution consistent with the target vessel; or 
•Typical ischemic symptoms referable to the target lesion; or 
•IVUS of the target lesion with a minimal lumen area (MLA) of ≤4 mm2 for non-left main lesions or ≤6 mm2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the 
plaque burden must also be ≥60%; or 
•FFR of the target lesion ≤0.80 
A target lesion revascularization for a diameter stenosis less than 50% might also be considered ischemia-driven by the Clinical Events Committee if there was a markedly positive 
functional study or ECG changes corresponding to the area served by the target lesion. 
Peri-procedural major adverse events: 
The composite rate of any of the following, occurring within 30 -days post procedure 
•Death 
•Stroke  
•Myocardial infarction 
•Ischemia -driven revascularization 
•TIMI major or minor bleeding 
•Transfusion ≥2 units of blood  
•Major arrhythmia (supraventricular tachycardia requiring cardioversion, ventricular tachycardia or fibrillation requiring treatment, or bradyarrhythmia requiring temporary or 
permanent pacemaker) 
•Any unplanned surgery or therapeutic radiologic procedure 
•Renal failure (serum creatinine increase by ≥0.5 mg/dL from baseline or need for dialysis ) 
•Sternal wound dehiscence 
•Infection requiring antibiotics 
•Prolonged intubation (>48 hours)  
•Post-pericardiotomy syndrome 
LE MANS (Study of UnprotectedLeft Main Stenting Versus Bypass Surgery) 
The major adverse events (MAE) were defined as all-cause mortality, acute myocardial infarction (defined as an increase in creatine phosphokinase (CPK)-MB to higher than 3 times 
the upper limit of normal after PCI and 5 times after CABG), repeat revascularization, acute heart failure (e.g., pulmonary edema, cardiogenic shock), or low output syndrome requiring 
intravenous inotropic agents and/or intra-aortic balloon pump support, post-procedural complications leading to reintervention, stroke, arrhythmia (ventricular fibrillation, ventricular 
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tachycardia, or atrial fibrillation), major bleeding requiring additional blood transfusion, and infections compromising post-procedural rehabilitation. Any cardiac mortality, acute 
myocardial infarction, stroke, repeat intervention, and/or acute/subacute in-stent thrombosis were considered MACCE.  
Target vessel failure was defined as any MACCE related to insufficient flow through the LMCA, and TVR as any repeat intervention (PCI or CABG) caused by a narrowing of the 
LMCA. The incidence of stent thrombosis was evaluated in accordance with the Academic Research Consortium Definitions of Stent Thrombosis 
SYNTAX (The other Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery trial) 
Deaths were considered cardiac unless an unequivocal, noncardiac cause was established.  
CVA was defined as a focal, central neurological deficit lasting >72 hours (h) which resulted in irreversible brain damage or body impairment.  
Repeat revascularization was defined as any repeat PCI or CABG. Complete revascularization was defined as the successful treatment of all eligible lesions identified during the 
Heart Team conference and estimated post procedure by the investigator.  
MI was based on previous studies, MI was defined in relation to intervention status as follows i) after allocation but before treatment: Q -wave (new pathological Q-waves in ≥2 leads 
lasting ≥0.04 seconds with CK-MB levels elevated above normal), and non-Q wave MI (elevation of CK levels >2 times the upper limit of normal [ULN] with positive CK-MB or 
elevation of CK levels to >2 times ULN without new Q-waves if no baseline CK-MB was available); ii) <7d after intervention: new Q-waves and either peak CK-MB/total CK >10% or 
plasma level of CK-MB 5x ULN; iii) 7d after intervention: new Q waves or peak CK-MB/total CK >10% or plasma level of CK-MB 5x ULN or plasma level of CK 5x ULN. The CK/CK-
MB enzyme levels were obtained and measured by a core laboratory for all randomized patients.  
Per protocol graft occlusion (GO) and stent thrombosis (ST) were considered acute if occurring ≤24h following the study procedure, sub-acute if occurring >24h to ≤30d following 
the study procedure and late after 30d. Per protocol graft occlusion and stent thrombosis were defined as either: i) clinical presentation of an acute coronary syndrome with 
documentation of a flow limiting thrombus or occlusion within a bypass graft or adjacent to the anastomosis of a previously bypassed coronary artery (for CABG patients) or within or 
adjacent to a previously successfully treated artery (for PCI patients); ii) a Q-wave MI in the territory of ≥1 treated vessels within first 30 days (d). 
Boudriot, et al 
Myocardial infarction was defined as an increase increatine kinase-MB activity >3 times the upper limit of normal after PCI and >5 times after CABG. In addition, standard 
electrocardiographic criteria were applied.  
The incidence of stent thrombosis was evaluated in accordance with the Academic Research Consortium definitions.  
Repeat revascularization was defined as anyrevascularization by CABG or PCI within 12 months, and was subdivided into target lesion revascularization of the ULM and distally 
located lesions or those of the right coronary artery.  
Erglis et al. 
Major adverse cardiac events (MACE) were defined as death, myocardial infarction (MI), and target lesion revascularization (TLR). Patients with more than 1 event were assigned the 
highest rank event.  
All deaths were considered to be of cardiac origin unless a noncardiac origin was diagnosed.  
Myocardial infarction (MI) was diagnosed by elevation of myocardial damage biomarkers: 3-fold in troponin I and 5-fold in MB fraction of creatine kinase.  
Target lesion revascularization was defined as a repeat intervention (surgical or percutaneous) to treat a luminal stenosis in the stent or within the 5-mm segments adjacent to the 
stent, including the ostium of the LAD artery and/or LCX artery. 
ISAR-LEFT-MAIN (Intracoronary Stenting and Angiographic Results: Drug-Eluting Stents for Unprotected Coronary Left Main 
Lesions) 
The diagnosis of MI required the presence of new significant Q waves on the electrocardiogram and/or elevation of CK-myocardial band isoform (or CK if the latter was not available) 
at least 2 times the upper limit of normal in no fewer than 2 blood samples.  
The TLR was defined as any repeat PCI involving the left main area or CABG involving at least 1 of the main left coronary vessels due to luminal renarrowing in the presence of 
symptoms or objective signs of ischemia.  
Stent thrombosis was defined according to Academic Research Consortium criteria (Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for 
standardized definitions. Circulation 2007;115:2344 –51.).  
Angiographic binary restenosis was defined as diameter stenosis >50%, measured by quantitative coronary angiography, in the left main area.  
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ISAR-LEFT-MAIN 2 (Intracoronary Stenting and Angiographic Results: Drug-Eluting Stents for Unprotected Coronary Left Main 
Lesions 2) 
The diagnosis of MI required the presence of new significant Q waves on electrocardiography and/or elevation of creatine kinase-MB isoform (or creatine kinase if the latter was not 
available) to at least 2 times the upper limit of normal in no fewer than 2 blood samples.  
Target lesion revascularization (TLR) was defined as any repeat PCI involving the left main area or CABG surgery involving at least one of the main left coronary vessels due to 
luminal renarrowing in the presence of symptoms or objective signs of ischemia.  
Stent thrombosis was defined according to Academic Research Consortium criteria (Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for 
standardized definitions. Circulation 2007;115:2344 –51).  
Angiographic binary restenosis was defined as diameter stenosis >50%, measured by quantitative coronary angiography, in the left main area. 
 19 
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Supplementary Table 3. Risk of bias of included randomized controlled trials. 21 
NOBLE   
Risk of bias Authors’ 
judgement 
Support for judgement 
Random sequence generation (selection bias) Low risk Computer-generated using permuted 
random blocks 
Allocation concealment (selection bias) Low risk Web-based computer randomization  
Blinding of participants and personnel (performance bias) High risk Blinding not applicable 
Blinding of outcome assessment (detection bias) Low risk Outcome assessors blinded 
Incomplete outcome data (attrition bias) Unclear risk Over 20% losses (31% losses to follow-up) 
Selective reporting (reporting bias) Low risk All expected outcomes included 
Other bias Unclear risk the primary endpoint timing changed 
EXCEL   
Risk of bias Authors’ 
judgement 
Support for judgement 
Random sequence generation (selection bias) Low risk Variable block random allocation 
Allocation concealment (selection bias) Low risk Interactive voice-based or Web-based 
system 
Blinding of participants and personnel (performance bias) High risk Blinding not applicable 
Blinding of outcome assessment (detection bias) Low risk Outcome assessors blinded 
Incomplete outcome data (attrition bias) Low risk 8% of participants were lost to follow-up; 
reasons reported 
Selective reporting (reporting bias) Low risk Study protocol is available, all expected 
outcomes included 
Other bias Low risk Free of other sources of bias 
LE MANS   
Risk of bias Authors’ 
judgement 
Support for judgement 
Random sequence generation (selection bias) Unclear risk Randomization stated to have been done 
but no method reported 
Allocation concealment (selection bias) Unclear risk Not specified 
Blinding of participants and personnel (performance bias) High risk Blinding not applicable 
Blinding of outcome assessment (detection bias) Low risk Blinded outcome assessors 
Incomplete outcome data (attrition bias) Low risk 11.4% of participants were lost to follow-up; 
reasons reported 
Selective reporting (reporting bias) Low risk Include all expected outcomes 
Other bias Low risk Free of other sources of bias 
PRECOMBAT   
Risk of bias Authors’ 
judgement 
Support for judgement 
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Random sequence generation (selection bias) Low risk Computer-generated random allocation 
sequence 
Allocation concealment (selection bias) Low risk Sealed envelopes concealed the allocation 
Blinding of participants and personnel (performance bias) High risk Blinding not applicable 
Blinding of outcome assessment (detection bias) Low risk Outcome assessors blinded 
Incomplete outcome data (attrition bias) Low risk 6.8% of participants were lost to follow-up; 
reasons reported 
Selective reporting (reporting bias) Low risk Study protocol is available, all expected 
outcomes included 
Other bias Low risk Free of other sources of bias 
SYNTAX   
Risk of bias Authors’ 
judgement 
Support for judgement 
Random sequence generation (selection bias) Low risk Variable block random allocation 
Allocation concealment (selection bias) Low risk Central allocation (Interactive Voice 
Response System) 
Blinding of participants and personnel (performance bias) High risk Blinding not applicable 
Blinding of outcome assessment (detection bias) Low risk Outcome assessors blinded 
Incomplete outcome data (attrition bias) Low risk 5.2% of participants were lost to follow-up; 
reasons reported 
Selective reporting (reporting bias) Low risk Study protocol is available, all expected 
outcomes included 
Other bias Low risk Free of other sources of bias 
Boudriot, et al   
Risk of bias Authors’ 
judgement 
Support for judgement 
Random sequence generation (selection bias) Low risk Computerized randomization program 
Allocation concealment (selection bias) Unclear risk Concealment of allocation was not reported 
Blinding of participants and personnel (performance bias) High risk Blinding not applicable 
Blinding of outcome assessment (detection bias) Low risk Blinded outcome assessors 
Incomplete outcome data (attrition bias) Low risk 0.5% of participants were lost to follow-up 
Selective reporting (reporting bias) Low risk All expected outcomes included 
Other bias Low risk Free of other sources of bias 
Erglis et al.   
Risk of bias   
Random sequence generation (selection bias) Unclear No sufficient information to allow judgement 
Allocation concealment (selection bias) Unclear No sufficient information to allow judgement 
Blinding of participants and personnel (performance bias) Unclear No sufficient information to allow judgement 
Blinding of outcome assessment (detection bias) Unclear No sufficient information to allow judgement 
Incomplete outcome data (attrition bias) Low risk No patient lost to follow-up 
Selective reporting (reporting bias) Unclear No sufficient information to allow judgement 
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Other bias Low risk There is no evidence of other bias 
ISAR-LEFT-MAIN   
Risk of bias   
Random sequence generation (selection bias) Low risk Computer-generated sequence 
Allocation concealment (selection bias) Low risk Sealed opaque envelopes 
Blinding of participants and personnel (performance bias) High-risk The manuscript doesn’t report information 
about the blinding of participants and 
personnel. We assume this is an open-label 
study 
Blinding of outcome assessment (detection bias) Low risk An events committee blinded to treatment 
allocation adjudicated all adverse clinical 
events. 
Incomplete outcome data (attrition bias) Low risk No patient lost to follow-up 
Selective reporting (reporting bias) Unclear No sufficient information to allow judgement 
Other bias High-risk The ISAR-LEFT-MAIN study was supported 
in part by an unrestricted grant from Cordis.  
ISAR-LEFT-MAIN 2   
Risk of bias   
Random sequence generation (selection bias) Low risk Randomisation was done by a web-based 
computer randomisation system 
Allocation concealment (selection bias) Low-risk Patients were assigned to the allocated 
treatment according to randomisation by the 
local research team.  
Blinding of participants and personnel (performance bias) High- risk Open-label study 
Blinding of outcome assessment (detection bias) High risk Open-label study 
Incomplete outcome data (attrition bias) High-risk 17 patients lost to follow-up, unlikely to 
have influenced results 
Selective reporting (reporting bias) Unclear No sufficient information to allow judgement 
Other bias Low-risk Aarhus University Hospital was the main 
sponsor of the trial. Biosensors provided an 
institutional research grant for the trial but 
had no role in the study design; in the 
collection, analysis, and interpretation of the 
data; in the writing of this report; or in the 
decision to submit the paper for publication. 
Expanded study abbreviations are as follows: : EXCEL = the Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization 22 
trial; LE MANS = Study of UnprotectedLeft Main Stenting Versus Bypass Surgery; NOBLE = The Nordic-Baltic-British left main revascularisation study; PRECOMBAT = the 23 
Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease trial; SYNTAX = 24 
the other Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery trial. ISAR-LEFT-MAIN (Intracoronary Stenting and Angiographic Results: 25 
Drug-Eluting Stents for Unprotected Coronary Left Main Lesions 26 
 27 
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Supplementary Table 4. Full Network meta-analytic estimates (expressed as log incidence rate ratio, IRR and 95% credible 28 
interval; statistical significance in bold) (BioES: Biolimus eluting stent; BMS: bare metal stents; CABG: coronary artery bypass 29 
grafting; EES: Everolimus eluting stent; MI: myocardial infarction; PES: paclitaxel-eluting stents; SES: sirolimus-eluting stents; ZES: 30 
zotarolimus-eluting stent) 31 
           BioES                       -1.166 (-3.262, 0.5108)    -0.1185 (-0.6011, 0.3578)     0.1858 (-0.4146, 0.7829)    -0.3287 (-0.9366, 0.2736)   -0.3186 (-0.9935, 0.3468)            0.192 (-0.7034, 1.083)    
  1.166 (-0.5108, 3.262)                BMS                             1.042 (-0.5564, 3.093)       1.348 (-0.2925, 3.43)             0.833 (-0.7845, 2.895)         0.843 (-0.8156, 2.939)                1.363 (-0.4249, 3.532)    
 0.1185 (-0.3578, 0.6011)     -1.042 (-3.093, 0.5564)              CABG                           0.3038 (-0.05129, 0.6653)   -0.2084 (-0.5795, 0.1597)   -0.1997 (-0.6654, 0.2652)            0.311 (-0.4428, 1.063)    
 -0.1858 (-0.7829, 0.4146)    -1.348 (-3.43, 0.2925)    -0.3038 (-0.6653, 0.05129)              EES                              -0.514 (-1.029, 0.0007923)   -0.505 (-1.093, 0.08261)             0.007237 (-0.659, 0.6691)  
 0.3287 (-0.2736, 0.9366)     -0.833 (-2.895, 0.7845)    0.2084 (-0.1597, 0.5795)    0.514 (-0.0007923, 1.029)              PES                                0.009336 (-0.4756, 0.4963)       0.5207 (-0.3156, 1.358)   
 0.3186 (-0.3468, 0.9935)     -0.843 (-2.939, 0.8156)    0.1997 (-0.2652, 0.6654)     0.505 (-0.08261, 1.093)   -0.009336 (-0.4963, 0.4756)             SES                                       0.512 (-0.371, 1.397)    
  -0.192 (-1.083, 0.7034)     -1.363 (-3.532, 0.4249)     -0.311 (-1.063, 0.4428)   -0.007237 (-0.6691, 0.659)   -0.5207 (-1.358, 0.3156)     -0.512 (-1.397, 0.371)                               ZES         
M
o
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          BioES                          -0.7653 (-2.094, 0.5427)      -1.087 (-1.864, -0.3979)   -1.148 (-1.983, -0.3826)      -0.7197 (-1.647, 0.1613)       -0.8682 (-1.881, 0.1073)             -0.2824 (-1.7, 1.26)    
 0.7653 (-0.5427, 2.094)             BMS                               -0.3304 (-1.433, 0.7578)   -0.3903 (-1.537, 0.7464)     0.04066 (-0.9842, 1.073)      -0.107 (-1.285, 1.074)                  0.4879 (-1.154, 2.221)   
  1.087 (0.3979, 1.864)    0.3304 (-0.7578, 1.433)                        CABG                      -0.05837 (-0.3818, 0.264)   0.3709 (-0.1532, 0.9082)     0.2247 (-0.4473, 0.9072)             0.8076 (-0.3876, 2.188)  
  1.148 (0.3826, 1.983)    0.3903 (-0.7464, 1.537)           0.05837 (-0.264, 0.3818)             EES                                0.4306 (-0.1877, 1.057)      0.2832 (-0.4617, 1.04)                 0.8652 (-0.2814, 2.211)  
 0.7197 (-0.1613, 1.647)  -0.04066 (-1.073, 0.9842)      -0.3709 (-0.9082, 0.1532)  -0.4306 (-1.057, 0.1877)             PES                                   -0.1469 (-0.7678, 0.4729)          0.4399 (-0.8755, 1.905)  
 0.8682 (-0.1073, 1.881)    0.107 (-1.074, 1.285)           -0.2247 (-0.9072, 0.4473)    -0.2832 (-1.04, 0.4617)     0.1469 (-0.4729, 0.7678)                        SES                                0.5882 (-0.7967, 2.112)  
   0.2824 (-1.26, 1.7)     -0.4879 (-2.221, 1.154)              -0.8076 (-2.188, 0.3876)    -0.8652 (-2.211, 0.2814)      -0.4399 (-1.905, 0.8755)        -0.5882 (-2.112, 0.7967)                        ZES            
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          BioES                                 0.9567 (0.01152, 2.033)    -0.641 (-1.003, -0.293)      -0.0982 (-0.5659, 0.3653)     -0.1277 (-0.6017, 0.3418)    0.0608 (-0.4646, 0.59)                 0.1264 (-0.5473, 0.8067)  
-0.9567 (-2.033, -0.01152)                     BMS                         -1.596 (-2.623, -0.7295)   -1.054 (-2.118, -0.1309)      -1.082 (-2.116, -0.1973)        -0.8956 (-1.975, 0.04512)          -0.832 (-1.994, 0.224)   
   0.641 (0.293, 1.003)              1.596 (0.7295, 2.623)                  CABG                             0.5432 (0.2455, 0.8497)     0.514 (0.2072, 0.8272)           0.7023 (0.3189, 1.097)              0.7689 (0.1983, 1.353)   
 0.0982 (-0.3653, 0.5659)        1.054 (0.1309, 2.118)       -0.5432 (-0.8497, -0.2455)                      EES                       -0.02982 (-0.4618, 0.4039)   0.1596 (-0.3316, 0.654)             0.2256 (-0.2644, 0.7221)  
 0.1277 (-0.3418, 0.6017)        1.082 (0.1973, 2.116)       -0.514 (-0.8272, -0.2072)      0.02982 (-0.4039, 0.4618)                          PES                      0.1886 (-0.225, 0.6081)           0.2553 (-0.3963, 0.9129)  
 -0.0608 (-0.59, 0.4646)           0.8956 (-0.04512, 1.975)   -0.7023 (-1.097, -0.3189)   -0.1596 (-0.654, 0.3316)   -0.1886 (-0.6081, 0.225)                             SES                            0.06595 (-0.6265, 0.7658)  
-0.1264 (-0.8067, 0.5473)        0.832 (-0.224, 1.994)         -0.7689 (-1.353, -0.1983)      -0.2256 (-0.7221, 0.2644)    -0.2553 (-0.9129, 0.3963)       -0.06595 (-0.7658, 0.6265)                       ZES            
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       BioES                                -1.001 (-1.895, -0.1452)       -0.5382 (-0.7923, -0.2897) -0.5147 (-0.8634, -0.1697)     -0.6938 (-1.086, -0.3051)          -0.7158 (-1.17, -0.2634)     -0.2929 (-0.9653, 0.3897)  
  1.001 (0.1452, 1.895)                    BMS                                0.4615 (-0.3563, 1.319)       0.4848 (-0.3656, 1.374)       0.3071 (-0.5049, 1.154)          0.285 (-0.5917, 1.191)          0.7091 (-0.3203, 1.772)   
 0.5382 (0.2897, 0.7923)    -0.4615 (-1.319, 0.3563)                    CABG                           0.02384 (-0.2147, 0.2622)   -0.1551 (-0.4557, 0.1429)      -0.1771 (-0.5554, 0.199)        0.2453 (-0.3767, 0.8807)  
 0.5147 (0.1697, 0.8634)    -0.4848 (-1.374, 0.3656)        -0.02384 (-0.2622, 0.2147)            EES                                  -0.1792 (-0.5603, 0.2039)     -0.2009 (-0.6472, 0.2449)      0.2222 (-0.3544, 0.8121)  
  0.6938 (0.3051, 1.086)    -0.3071 (-1.154, 0.5049)          0.1551 (-0.1429, 0.4557)   0.1792 (-0.2039, 0.5603)                  PES                                  -0.02207 (-0.4051, 0.3617)     0.401 (-0.2901, 1.101)   
  0.7158 (0.2634, 1.17)     -0.285 (-1.191, 0.5917)             0.1771 (-0.199, 0.5554)    0.2009 (-0.2449, 0.6472)       0.02207 (-0.3617, 0.4051)                    SES                                  0.4237 (-0.3051, 1.162)   
 0.2929 (-0.3897, 0.9653)   -0.7091 (-1.772, 0.3203)        -0.2453 (-0.8807, 0.3767)  -0.2222 (-0.8121, 0.3544)   -0.401 (-1.101, 0.2901)             -0.4237 (-1.162, 0.3051)                         ZES             
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Figure legends 33 
Central Picture: Different stent generations vs. CABG for unprotected left main 34 
disease (BioES: biolimus eluting stent; BMS: bare metal stent; CABG: coronary 35 
artery bypass grafting; EES: everolimus eluting stent; MI: myocardial infarction; PES: 36 
paclitaxel-eluting stents; SES: sirolimus-eluting stents; ZES: zotarolimus-eluting 37 
stents) 38 
Figure 1. Network plot of relevant studies. Circles represent each revascularization 39 
strategy as a node and lines represent the direct comparisons. The extent of circle 40 
indicates the number of patients receiving each revascularization strategy and the 41 
line thickness indicates the number of studies included in each comparison (Bio-ES: 42 
biolimus eluting stent; BMS: bare metal stent; CABG: coronary artery bypass 43 
grafting; EES: everolimus eluting stent; PES: paclitaxel-eluting stents; SES: 44 
sirolimus-eluting stents; ZES: zotarolimus-eluting stents)  45 
Figure 2. Network meta-analysis estimates (expressed as incidence rate ratio, IRR, 46 
with relative 95% Credible interval, CrI) for different stent generations (CABG as 47 
comparator) (BioES: biolimus eluting stent; BMS: bare metal stent; CABG: coronary 48 
artery bypass grafting; EES: everolimus eluting stent; MI: myocardial infarction; PES: 49 
paclitaxel-eluting stents; SES: sirolimus-eluting stents; ZES: zotarolimus-eluting 50 
stents)  51 
Figure 3. Network meta-analysis estimates (express as incidence rate ratio, IRR, 52 
with relative 95% Credible interval, CrI) for individual stent types (CABG as 53 
comparator). (BioES: biolimus eluting stent; BMS: bare metal stent; CABG: coronary 54 
artery bypass grafting; EES: everolimus eluting stent; MI: myocardial infarction; PCI: 55 
 35 
 
percutaneous coronary intervention; PES: paclitaxel-eluting stents; SES: sirolimus-56 
eluting stents; ZES: zotarolimus-eluting stents) 57 
Figure 4. Pairwise pooled and subgroup meta-analysis according to different stent 58 
generations for the composite of death/MI/stroke (BioES: biolimus eluting stent; 59 
BMS: bare metal stent; CABG: coronary artery bypass grafting; EES: everolimus 60 
eluting stent; MI: myocardial infarction; PCI: percutaneous coronary intervention; 61 
PES: paclitaxel-eluting stents; SES: sirolimus-eluting stents; ZES: zotarolimus-62 
eluting stents).  63 
Figure 5. Pairwise pooled and subgroup meta-analysis according to different stent 64 
generations for repeat revascularization (BioES: biolimus eluting stent; BMS: bare 65 
metal stent; CABG: coronary artery bypass grafting; EES: everolimus eluting stent; 66 
MI: myocardial infarction; PCI: percutaneous coronary intervention; PES: paclitaxel-67 
eluting stents; SES: sirolimus-eluting stents; ZES: zotarolimus-eluting stents). 68 
Supplementary Figure 1. Flow diagram of study selection. CABG = coronary artery 69 
bypass graft surgery; CENTRAL = the Cochrane Central Register of Controlled 70 
Trials; LMD = left main disease; PCI = percutaneous coronary intervention; RCT: 71 
randomized controlled trials 72 
Supplementary Figure 2. Median treatment effect and the 95% credible interval (for 73 
each type of stents compared to CABG) across Syntax score values for the 74 
composite of death/MI/stroke (BioES: biolimus eluting stent; BMS: bare metal stent; 75 
CABG: coronary artery bypass grafting; EES: everolimus eluting stent; MI: 76 
myocardial infarction; PCI: percutaneous coronary intervention; PES: paclitaxel-77 
eluting stent; SES: sirolimus-eluting stent; ZES: zotarolimus-eluting stent) 78 
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Supplementary Figure 3. Median treatment effect and the 95% credible interval (for 79 
each type of stents compared to CABG) across Syntax score values for repeat 80 
revascularization (BioES: biolimus eluting stent; BMS: bare metal stent; CABG: 81 
coronary artery bypass grafting; EES: everolimus eluting stent; MI: myocardial 82 
infarction; PCI: percutaneous coronary intervention; PES: paclitaxel-eluting stent; 83 
SES: sirolimus-eluting stent; ZES: zotarolimus-eluting stent) 84 
Supplementary Figure 4.  Comparison of direct and indirect estimates to assess 85 
inconsistency (BioES: biolimus eluting stent; BMS: bare metal stent; CABG: coronary 86 
artery bypass grafting; EES: everolimus eluting stent; MI: myocardial infarction; PCI: 87 
percutaneous coronary intervention; PES: paclitaxel-eluting stent; SES: sirolimus-88 
eluting stent; ZES: zotarolimus-eluting stent89 
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